InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,170.28
(
-1.94%
)
Post# of 222198
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Zorax

Send PM Follow Ignore
Followers 182
Posts 51564
Boards Moderated 10
Alias Born 12/20/2004

Zorax

Re: namtae post# 129729

Friday, 12/01/2017 12:35:41 PM

Friday, December 01, 2017 12:35:41 PM

Post# of 222198

Not unusual to dose previously treated, unresponsive patients with a short life expectancy in Phase 1, which is where toxicity, safety & dosage outcomes are studied.

Wouldnt want to first test experimental treatments on newly diagnosed or treatment naive patients for fear of severe adverse reactions or risk of life

This is why the preferred patients unfortunately, are the ones with a short life expectancy


Is there any at all links to such a unrealistic statement?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up